SHREE GANESH REMEDIES LTD (SGRL) financials

SHREE GANESH REMEDIES LTD (SGRL) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Shree Ganesh Remedies is an Ankleshwar-based manufacturer of pharmaceutical/API intermediates and specialty and fine chemicals. It also provides custom synthesis and contract manufacturing for pharmaceutical, agrochemical, polymer, and electronics customers across more than 20 countries.[1][2]

Market Cap: ₹875Cr.
Current Price: ₹680
Stock P/E: 56.6
ROE: 10.8%
ROCE: 14.2%
Book Value: ₹127
Dividend Yield: 0.00%
52W High / Low: ₹759/381

In Jun 2026, SHREE GANESH REMEDIES LTD (SGRL) reported sales ₹14.36 Cr and net profit ₹1.12 Cr.

Annual TTM: sales ₹99 Cr, net profit ₹15 Cr.

Shareholding: Promoters 72.83% (Jun 2026), FIIs 0.00% (Jun 2026), DIIs 0.52% (Jun 2026), Public 26.65% (Jun 2026), No. of Shareholders 7,822% (Jun 2026).

SGRL quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	32.33	27.05	24.43	24.67	30.32	21.11	33.20	14.36
Expenses	21.02	17.14	14.55	17.37	20.70	14.38	21.82	11.01
Operating Profit	11.31	9.91	9.88	7.30	9.62	6.73	11.38	3.35
OPM %	34.98%	36.64%	40.44%	29.59%	31.73%	31.88%	34.28%	23.33%
Other Income	0.19	0.71	2.29	0.66	0.69	0.66	1.02	0.94
Interest	0.43	0.38	0.96	0.94	1.01	0.74	0.88	0.32
Depreciation	2.42	2.70	2.42	2.42	2.59	2.67	2.80	2.44
Profit before tax	8.65	7.54	8.79	4.60	6.71	3.98	8.72	1.53
Tax %	25.78%	27.85%	24.80%	25.00%	26.23%	22.36%	28.10%	27.45%
Net Profit	6.42	5.43	6.60	3.45	4.96	3.10	6.27	1.12
EPS in Rs	5.00	4.23	5.14	2.69	3.86	2.41	4.88	0.87
Raw PDF	—	—	—	—	—	—	—	—

SGRL profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	58	49	71	91	126	109	109	99
Expenses	47	35	53	68	84	69	74	68
Operating Profit	11	14	18	23	42	39	35	31
OPM %	19%	28%	25%	26%	33%	36%	32%	31%
Other Income	4	2	4	1	3	4	3	3
Interest	0	0	0	0	1	2	4	3
Depreciation	2	3	3	4	6	10	10	10
Profit before tax	13	13	18	20	38	31	24	21
Tax %	24%	25%	26%	25%	26%	26%	26%	—
Net Profit	10	10	13	15	28	23	18	15
EPS in Rs	7.52	7.62	10.47	11.86	21.97	18.00	13.84	12.02
Dividend Payout %	14%	18%	4%	2%	2%	0%	0%	—

SGRL balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	9	9	10	12	13	13	13	13
Reserves	25	33	40	50	75	109	132	150
Borrowings	1	2	0	0	33	36	38	31
Other Liabilities	7	8	10	15	18	12	8	14
Total Liabilities	41	52	61	77	138	171	192	208
Fixed Assets	14	16	19	27	58	81	95	105
CWIP	0	0	2	3	15	17	9	13
Investments	4	7	3	0	0	5	18	13
Other Assets	23	29	37	47	64	69	70	78
Total Assets	41	52	61	77	138	171	192	208

SGRL cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-5	4	3	13	17	30	31	24
Cash from Investing Activity	-0	-3	-1	-12	-51	-33	-35	-9
Cash from Financing Activity	-0	-0	-1	-1	39	10	-1	-12
Net Cash Flow	-5	1	2	0	5	7	-6	3
Free Cash Flow	-5	4	3	-2	-32	-1	7	7
CFO/OP	-60%	35%	24%	75%	73%	92%	104%	81%

SGRL shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	70.49%	72.80%	72.80%	72.80%	72.80%	72.80%	72.83%	72.83%
FIIs	0.01%	0.01%	0.01%	0.01%	0.01%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.52%
Public	29.50%	27.19%	27.20%	27.20%	27.19%	27.20%	27.16%	26.65%
No. of Shareholders	8,508	8,695	8,978	9,166	8,752	8,442	8,058	7,822

SGRL key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	101	104	99	94	112	59	75	109
Inventory Days	125	56	206	132	138	156	223	209
Days Payable	75	39	101	92	118	51	61	82
Cash Conversion Cycle	151	120	205	134	133	164	238	236
Working Capital Days	145	102	158	133	122	89	111	128
ROCE %	27%	33%	28%	33%	22%	28%	19%	14%

SGRLUpdated 28 Sept 2026, 20:47

Shree Ganesh Remedies Ltd

SGRLUpdated 28 Sept 2026, 20:47

Market Cap

₹875Cr.

Current Price

₹680

High / Low

₹759/381

Stock P/E

56.6

ROE10.8%

ROCE14.2%

Book Value₹127

Face Value₹10.0

Dividend Yield0.00%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	26.72	0.01	20.16	0.73	1.02	6.26	27.64	4.54	3.55
Sep 2023	33.42	0.01	24.19	0.8	1.41	8.61	23.81	6.55	5.12
Dec 2023	27.97	0.02	19.76	1.11	1.88	7.42	35.31	4.8	3.75
Mar 2024	37.33	0.15	20.39	1.32	1.86	16.25	22.46	12.59	9.84
Jun 2024	24.78	0.32	16.65	0.54	2.02	6.33	26.7	4.65	3.62
Sep 2024	32.33	0.43	21.02	0.19	2.42	8.65	25.78	6.42	5
Dec 2024	27.05	0.38	17.14	0.71	2.7	7.54	27.85	5.43	4.23
Mar 2025	24.43	0.96	14.55	2.29	2.42	8.79	24.8	6.6	5.14
Jun 2025	24.67	0.94	17.37	0.66	2.42	4.6	25	3.45	2.69
Sep 2025	30.32	1.01	20.7	0.69	2.59	6.71	26.23	4.96	3.86
Dec 2025	21.11	0.74	14.38	0.66	2.67	3.98	22.36	3.1	2.41
Mar 2026	33.2	0.88	21.82	1.02	2.8	8.72	28.1	6.27	4.88
Jun 2026	14.36	0.32	11.01	0.94	2.44	1.53	27.45	1.12	0.87

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	16	0	14	0	1	2	33	1	7.94
Mar 2016	16	0	14	0	1	2	34	1	6.75
Mar 2017	20	0	16	0	1	4	33	3	16.5
Mar 2018	27	0	22	2	1	6	28	5	3.66
Mar 2019	35	0	26	1	1	9	28	6	4.88
Mar 2020	58	0	47	4	2	13	24	10	7.52
Mar 2021	49	0	35	2	3	13	25	10	7.62
Mar 2022	71	0	53	4	3	18	26	13	10.47
Mar 2023	91	0	68	1	4	20	25	15	11.86
Mar 2024	126	1	84	3	6	38	26	28	21.97
Mar 2025	109	2	69	4	10	31	26	23	18
Mar 2026	109	4	74	3	10	24	26	18	13.84
TTM	99	3	68	3	10	21	—	15	12.02

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	72.83%
DIIs	0.52%
Public	26.65%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	69.33%	0%	0%	30.67%
Dec 2023	69.33%	0%	0%	30.66%
Mar 2024	69.33%	0%	0%	30.67%
Jun 2024	69.33%	0.01%	0%	30.66%
Sep 2024	70.49%	0.01%	0%	29.5%
Dec 2024	72.8%	0.01%	0%	27.19%
Mar 2025	72.8%	0.01%	0%	27.2%
Jun 2025	72.8%	0.01%	0%	27.2%
Sep 2025	72.8%	0.01%	0%	27.19%
Dec 2025	72.8%	0%	0%	27.2%
Mar 2026	72.83%	0%	0%	27.16%
Jun 2026	72.83%	0%	0.52%	26.65%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	1	12	0	2	15	4	0	0	11	15
Mar 2016	1	13	0	2	16	4	0	0	11	16
Mar 2017	1	15	0	5	21	4	0	0	17	21
Mar 2018	9	20	2	5	36	6	0	4	25	36
Mar 2019	9	25	1	7	41	14	0	4	23	41
Mar 2020	9	33	2	8	52	16	0	7	29	52
Mar 2021	10	40	0	10	61	19	2	3	37	61
Mar 2022	12	50	0	15	77	27	3	0	47	77
Mar 2023	13	75	33	18	138	58	15	0	64	138
Mar 2024	13	109	36	12	171	81	17	5	69	171
Mar 2025	13	132	38	8	192	95	9	18	70	192
Mar 2026	13	150	31	14	208	105	13	13	78	208

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	-1	1	0	-1
Mar 2016	-2	1	0	0
Mar 2017	2	0	0	2
Mar 2018	-1	-3	8	4
Mar 2019	-5	0	0	-5
Mar 2020	4	-3	0	1
Mar 2021	3	-1	-1	2
Mar 2022	13	-12	-1	0
Mar 2023	17	-51	39	5
Mar 2024	30	-33	10	7
Mar 2025	31	-35	-1	-6
Mar 2026	24	-9	-12	3

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	93	133	136	78	101	104	99	94	112	59	75	109
Inventory Days	132	130	103	102	125	56	206	132	138	156	223	209
Days Payable	43	32	90	43	75	39	101	92	118	51	61	82
Cash Conversion Cycle	183	232	149	137	151	120	205	134	133	164	238	236
Working Capital Days	160	202	172	128	145	102	158	133	122	89	111	128
ROCE %	16%	12%	26%	27%	27%	33%	28%	33%	22%	28%	19%	14%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of SHREE GANESH REMEDIES LTD (SGRL)?

The reported market capitalisation for SHREE GANESH REMEDIES LTD (SGRL) is ₹875Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of SGRL?

The current price shown for SHREE GANESH REMEDIES LTD (SGRL) on Fincrux is ₹680 with a 52-week high/low of ₹759/381.

What is the P/E ratio of SHREE GANESH REMEDIES LTD (SGRL)?

The stock P/E for SHREE GANESH REMEDIES LTD (SGRL) is 56.6 on Fincrux, with ROE at 10.8% and ROCE at 14.2%.

What were SGRL latest quarterly results?

For Jun 2026, SHREE GANESH REMEDIES LTD (SGRL) reported sales ₹14.36 Cr and net profit ₹1.12 Cr (figures in ₹ crore unless noted).

What are SGRL annual sales and net profit?

For TTM, SHREE GANESH REMEDIES LTD (SGRL) shows sales of ₹99 Cr and net profit of ₹15 Cr on the Fincrux profit & loss statement.

Who owns SHREE GANESH REMEDIES LTD (SGRL)?

Latest shareholding for SHREE GANESH REMEDIES LTD (SGRL) on Fincrux: Promoters 72.83% (Jun 2026), FIIs 0.00% (Jun 2026), DIIs 0.52% (Jun 2026), Public 26.65% (Jun 2026), No. of Shareholders 7,822% (Jun 2026).

Where can I find SHREE GANESH REMEDIES LTD (SGRL) financials?

SHREE GANESH REMEDIES LTD (SGRL) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show SGRL balance sheet and cash flow?

Yes. The SHREE GANESH REMEDIES LTD (SGRL) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 28 September 2026 at 20:47